1
|
Frix AN, Schoneveld L, Ladang A, Henket M, Duysinx B, Vaillant F, Misset B, Moutschen M, Louis R, Cavalier E, Guiot J. Could KL-6 levels in COVID-19 help to predict lung disease? Respir Res 2020; 21:309. [PMID: 33234132 PMCID: PMC7683867 DOI: 10.1186/s12931-020-01560-4] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Accepted: 10/29/2020] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Coronavirus disease COVID-19 has become a public health emergency of international concern. Together with the quest for an effective treatment, the question of the post-infectious evolution of affected patients in healing process remains uncertain. Krebs von den Lungen 6 (KL-6) is a high molecular weight mucin-like glycoprotein produced by type II pneumocytes and bronchial epithelial cells. Its production is raised during epithelial lesions and cellular regeneration. In COVID-19 infection, KL-6 serum levels could therefore be of interest for diagnosis, prognosis and therapeutic response evaluation. MATERIALS AND METHODS Our study retrospectively compared KL-6 levels between a cohort of 83 COVID-19 infected patients and two other groups: healthy subjects (n = 70) on one hand, and a heterogenous group of patients suffering from interstitial lung diseases (n = 31; composed of 16 IPF, 4 sarcoidosis, 11 others) on the other hand. Demographical, clinical and laboratory indexes were collected. Our study aims to compare KL-6 levels between a COVID-19 population and healthy subjects or patients suffering from interstitial lung diseases (ILDs). Ultimately, we ought to determine whether KL-6 could be a marker of disease severity and bad prognosis. RESULTS Our results showed that serum KL-6 levels in COVID-19 patients were increased compared to healthy subjects, but to a lesser extent than in patients suffering from ILD. Increased levels of KL-6 in COVID-19 patients were associated with a more severe lung disease. DISCUSSION AND CONCLUSION Our results suggest that KL-6 could be a good biomarker to assess ILD severity in COVID-19 infection. Concerning the therapeutic response prediction, more studies are necessary.
Collapse
Affiliation(s)
- A N Frix
- Department of Respiratory Medicine, CHU Liège, University Hospital of Liège, Domaine Universitaire du Sart-Tilman, B35, 4000, Liège, Belgium.
| | - L Schoneveld
- Department of Clinical Chemistry, CHU Liège, University Hospital of Liège, Domaine Universitaire du Sart-Tilman, B35, 4000, Liège, Belgium
| | - A Ladang
- Department of Clinical Chemistry, CHU Liège, University Hospital of Liège, Domaine Universitaire du Sart-Tilman, B35, 4000, Liège, Belgium
| | - M Henket
- Department of Respiratory Medicine, CHU Liège, University Hospital of Liège, Domaine Universitaire du Sart-Tilman, B35, 4000, Liège, Belgium
| | - B Duysinx
- Department of Respiratory Medicine, CHU Liège, University Hospital of Liège, Domaine Universitaire du Sart-Tilman, B35, 4000, Liège, Belgium
| | - F Vaillant
- Department of Respiratory Medicine, CHU Liège, University Hospital of Liège, Domaine Universitaire du Sart-Tilman, B35, 4000, Liège, Belgium
| | - B Misset
- Intensive Care Unit, CHU Liège, University Hospital of Liège, Domaine Universitaire du Sart-Tilman, B35, 4000, Liège, Belgium
| | - M Moutschen
- Department of Infectious Diseases and Immunology, CHU Liège, University Hospital of Liège, Domaine Universitaire du Sart-Tilman, B35, 4000, Liège, Belgium
| | - R Louis
- Department of Respiratory Medicine, CHU Liège, University Hospital of Liège, Domaine Universitaire du Sart-Tilman, B35, 4000, Liège, Belgium
| | - E Cavalier
- Department of Clinical Chemistry, CHU Liège, University Hospital of Liège, Domaine Universitaire du Sart-Tilman, B35, 4000, Liège, Belgium
| | - J Guiot
- Department of Respiratory Medicine, CHU Liège, University Hospital of Liège, Domaine Universitaire du Sart-Tilman, B35, 4000, Liège, Belgium
| |
Collapse
|
2
|
Louis R, Calmes D, Frix AN, Schleich F. [COVID-19 and asthma]. Rev Med Liege 2020; 75:130-132. [PMID: 33211435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Given the prominent role of respiratory viruses in asthma exacerbations it has been feared that the SARS-CoV-2 pandemic may result in massive irruption of asthmatic patients in the hospital emergency departments. It seems, however, that asthma is not a particular risk factor for SARS-COV-2 infection nor for death resulting from severe infection. Inhaled corticosteroids (ICS) were found to reduce expression of ACE2 receptor in sputum cells, thereby maybe reducing the risk of lung infection. Only the more severe asthmatic patients treated with oral corticoids or high dose ICS were found to be at risk of death, presumably because of associated comorbidities. Biologicals directed towards IgE or interleukin-5 do not seem to confer an increased risk of severe infection.
Collapse
Affiliation(s)
- R Louis
- Service d'Allergologie-Pneumologie, CHU Liège, Belgique
| | - D Calmes
- Service d'Allergologie-Pneumologie, CHU Liège, Belgique
| | - A N Frix
- Service d'Allergologie-Pneumologie, CHU Liège, Belgique
| | - F Schleich
- Service d'Allergologie-Pneumologie, CHU Liège, Belgique
| |
Collapse
|
3
|
Schleich F, Frix AN, Paulus V, Guissard F, Sanchez CE, Henket ME, Louis R. [Asthma : the contribution of biotherapies]. Rev Med Liege 2020; 75:350-355. [PMID: 32496678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Asthma is a chronic heterogeneous airway disease. There are different asthma inflammatory phenotypes with various responses to treatment and different disease severities. When asthma requires chronic systemic corticosteroids or hospitalizations despite maximal inhaled therapies in asthmatic patients in whom comorbidities have been managed and who are considered as compliant, the pulmonologist may propose biological treatment to reduce exacerbations and the dose of systemic corticosteroids. During the last ten years, the number of biologics for the management of type-2 severe asthma has increased. Anti-IgE monoclonal antibodies (omalizumab) are available for more than ten years and recommended in severe allergic asthma. New biologics are now available to block IL-5 (mepolizumab, reslizumab) or its receptor (benralizumab). These treatments allow a reduction of exacerbations and of the dose of systemic corticosteroids, an improvement in asthma control, in asthma quality of life and for some of them, an increase in lung function. New biologics will soon be available in Belgium for the management of severe asthma. In addition to the improvement of asthma control in severe asthma, biological treatments have improved the understanding of the mechanisms leading to severe asthma.
Collapse
Affiliation(s)
- F Schleich
- Clinique de l'Asthme, Service de Pneumologie, CHU Liège, Belgique
| | - A N Frix
- Clinique de l'Asthme, Service de Pneumologie, CHU Liège, Belgique
| | - V Paulus
- Clinique de l'Asthme, Service de Pneumologie, CHU Liège, Belgique
| | - F Guissard
- Clinique de l'Asthme, Service de Pneumologie, CHU Liège, Belgique
| | - C E Sanchez
- Clinique de l'Asthme, Service de Pneumologie, CHU Liège, Belgique
| | - M E Henket
- Clinique de l'Asthme, Service de Pneumologie, CHU Liège, Belgique
| | - R Louis
- Clinique de l'Asthme, Service de Pneumologie, CHU Liège, Belgique
| |
Collapse
|
4
|
Frix AN, Schleich F, Paulus V, Guissard F, Henket M, Louis R. Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma. Biochem Pharmacol 2020; 179:113944. [PMID: 32240649 DOI: 10.1016/j.bcp.2020.113944] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2020] [Accepted: 03/27/2020] [Indexed: 11/17/2022]
Abstract
BACKGROUND Omalizumab arose as a therapeutic option in patients suffering from moderate to severe refractory allergic asthma. It acts as a humanized monoclonal antibody neutralizing circulating IgE antibodies. Randomized clinical trials and real life clinical studies have already confirmed benefits, cost-effectiveness and applicability of the medication. METHOD Our study retrospectively reports on the clinical outcomes and airway inflammation in 157 severe allergic asthmatics who were initiated with omalizumab between 2007 and 2019. RESULTS After 4 months of therapy, 76% of the patients were judged to have benefited from omalizumab and were admitted to prolonged treatment. During follow-up, we observed an improvement in asthma control, quality of life and spirometric performance. There was also a sustained reduction in exacerbation rate over the years. As for T2 biomarkers, FeNO significantly decreased and, in a subgroup of patients who had repeated sputum inductions, there was also significant reduction in sputum eosinophils but no change in blood eosinophil count. Lastly, we found a correlation between high FeNO levels at baseline and reduction in ACQ scores at 1 year. CONCLUSION We conclude that omalizumab shows effectiveness in severe allergic asthma in a real life setting, by reducing exacerbation rate, improving patient perspective outcomes and airway calibre, together with reducing type-2 airway inflammation.
Collapse
Affiliation(s)
- A N Frix
- Department of Respiratory Medicine, University Hospital Liège, Liège, Belgium.
| | - F Schleich
- Department of Respiratory Medicine, University Hospital Liège/GIGA Research Group, University of Liège, Liège, Belgium
| | - V Paulus
- Department of Respiratory Medicine, University Hospital Liège/GIGA Research Group, University of Liège, Liège, Belgium
| | - F Guissard
- Department of Respiratory Medicine, University Hospital Liège/GIGA Research Group, University of Liège, Liège, Belgium
| | - M Henket
- Department of Respiratory Medicine, University Hospital Liège/GIGA Research Group, University of Liège, Liège, Belgium
| | - R Louis
- Department of Respiratory Medicine, University Hospital Liège/GIGA Research Group, University of Liège, Liège, Belgium
| |
Collapse
|